Benralizumab, AZ's potential new medicine and anti-eosinophil monoclonal antibody, has been well tolerated and achieved the primary endpoint in two pivotal Phase III registrational trials.
This demonstrates significant reductions in the annual asthma exacerbation rate compared to placebo.